MRD testing

Fremont, California | April 13, 2026 Personalis, Inc. has unveiled new data showcasing its ultrasensitive ctDNA-based cancer monitoring platform,...

Toronto, Ontario, December 18, 2025 — Telo Genomics Corp. has initiated a new retrospective blood-based minimal residual disease (MRD)...

TORONTO, Ontario — November 13, 2025: Telo Genomics announced it will present its groundbreaking individual-cell MRD risk-assessment technology at...